Elabscience
SKU:E-CL-H0698
Human LIFR(Leukemia Inhibitory Factor Receptor) CLIA Kit
Human LIFR(Leukemia Inhibitory Factor Receptor) CLIA Kit
Couldn't load pickup availability
The HUMAN LIFR (Leukemia Inhibitory Factor Receptor) CLIA Kit is a cutting-edge diagnostic tool designed for the accurate detection and quantification of LIFR in human samples. This highly sensitive and specific kit utilizes the Chemiluminescent Immunoassay (CLIA) technique, which ensures reliable and reproducible results. LIFR is a crucial receptor involved in various cellular processes, including cell growth, differentiation, and survival. By measuring the levels of LIFR in patient samples, this CLIA kit provides valuable insights into the functioning of this receptor and its potential implications in disease progression.
This CLIA kit offers several key advantages over traditional diagnostic methods. Firstly, its high sensitivity allows for the detection of even low levels of LIFR, enabling early diagnosis and monitoring of diseases associated with LIFR dysregulation. Additionally, the kit's specificity ensures minimal cross-reactivity with other molecules, guaranteeing accurate and reliable results. The Chemiluminescent Immunoassay technique employed by this kit offers a wide dynamic range, allowing for the quantification of LIFR levels across a broad spectrum. This versatility makes it suitable for a range of applications, from basic research to clinical diagnostics.
The HUMAN LIFR CLIA Kit is user-friendly and time-efficient, making it an ideal choice for laboratories and healthcare professionals. The kit includes all necessary components, including pre-coated microplates, detection reagents, and standards, ensuring convenience and ease of use. The straightforward protocol and short incubation times streamline the workflow, enabling quick and efficient analysis of patient samples. With its high accuracy, sensitivity, and ease of use, this CLIA kit is an invaluable tool for researchers and clinicians alike, facilitating the study and understanding of LIFR-related diseases and potentially leading to improved patient outcomes.
Share
